Genzyme's Manufacturing Problems

Genzyme looks increasingly vulnerable after the temporary closure of its Allston manufacturing facility resulted in shortages of one of its primary products, Cerezyme. Analysts remain divided on the long-term consequences, but there's no denying the the gaffes have created an opening for medicines from competitors Shire and Protalix.

In a town hall-style teleconference held August 26, Genzyme Corp.'s long-time CEO Henri Termeer admitted that the shutdown of its Allston Landing, MA-based manufacturing facility because of viral contamination earlier this summer resulted in "many, big expensive lessons." We are only beginning to know just how expensive the tutorial could be.

In early August, the company revealed 2009 sales of its blockbuster Gaucher disease drug imiglucerase (Cerezyme) would be reduced from...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Leadership

Vigya test infogram - Clone

add a desc test

Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future clone3

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Vigya test infogram

add a desc test

More from In Vivo

Vigya test infogram

add a desc test

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.